Experience of using a combined melatonin-containing drug in the correction of sleep disorders in women

A review of existing research suggests that women are more likely to experience sleep disorders than men. Chronic sleep deprivation results in the activation of the hypothalamic-pituitary system and sympathetic nervous system, which increases the risk of menstrual disorders, ovarian dysfunction, spontaneous abortion, decreased ovarian reserve in women over 35 years of age, and low effectiveness of in vitro fertilization in women with infertility. Sleep disorders such as hypersomnia and insomnia associated with premenstrual syndrome and premenstrual dysphoric disorder have been described. Sleep disorders in women with polycystic ovary syndrome are almost twice as common as in healthy women of the same age. Insomnia is a common complaint in menopausal transition period and in postmenopause in more than half of women.

The results of numerous studies emphasize the importance of diagnostics and treatment of sleep disorders for effective correction of the underlying disease that leads to reproductive impairment and reduced quality of life in women.

The first-line drug choice in the treatment of insomnia are herbal sedatives and melatonin. Melatonin is a pleiotropic hormone, produced by the epiphysis, that regulates the circadian and seasonal rhythms of physiological functions of the body. It affects not only sleep-wake cycles, but also neuronal development, metabolic processes, protection and regulation of the immune, endocrine and reproductive systems.

SonNorm Duo is a combined drug containing melatonin, peppermint leaf oil and motherwort herb extract, which has adaptogenic and sedative effect, helps to reduce the nervous system excitability, reduce anxiety and excitement, improve sleep quality; it also normalizes circadian rhythms, including the sleep-wakefulness cycle and adaptation of weather-sensitive people to weather changes. Due to the gradual release of its components, SonNorm Duo has a higher clinical efficacy relative to mono-melatonin-containing drugs, as well as a high safety profile, and can be used with hormone therapy.

Conclusion: The use of the combined drug SonNorm Duo in clinical practice confirms its efficacy and safety in women of reproductive and menopausal age.